US20240173339
2024-05-30
Human necessities
A61K31/658
Innovative formulations are designed to manage depression, anxiety, and PTSD using a combination of cannabinoids. These formulations include tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) in specific weight ratios that optimize their therapeutic effects. For mental health conditions, the ratios can vary, such as 0-1:4-20:10-25, with examples like 1:5:20 or 0:20:10.
Cannabinoids have been shown to have significant effects on mental health. CBD has demonstrated anxiolytic and antidepressant properties, potentially through mechanisms involving serotonin receptors and the modulation of endocannabinoids. THC acts on the CB1 receptor, influencing neurotransmitter release and exhibiting psychoactive effects. CBC has been identified as having anti-inflammatory and antidepressant properties as well, contributing to the overall efficacy of the formulations.
Formulations aimed at improving sleep quality also utilize cannabinoids. These combinations include THC, CBC, and CBD in ratios such as 1:0-5:15-25. The goal is to address insomnia and enhance overall sleep quality, which can be affected by various factors including stress and anxiety. The formulations may help individuals manage both chronic and occasional sleep disturbances.
The interaction between different cannabinoids can lead to enhanced therapeutic effects. For instance, CBD has been shown to work synergistically with THC, potentially amplifying the analgesic effects of cannabis extracts. The combination of these cannabinoids in specific ratios aims to maximize their benefits for both mental health management and sleep aid.
The cannabinoid formulations offer promising alternatives for individuals seeking relief from mental health issues or sleep disorders. By optimizing the ratios of THC, CBC, and CBD, these formulations could provide effective solutions for those with limited options in current treatments for depression, anxiety, PTSD, and insomnia.